| HOME >> MEDICINE >> TECHNOLOGY |
Mary Anne Rhyne 919-483-2839
US Analyst/Investor inquiries:
Frank Murdolo 215-751-7002
Tom Curry 215-751-5419
REFERENCES
(1) Bussel, JB., Cheng, G., et al. Long-term safety and efficacy of oral eltrombopag for the treatment of subjects with idiopathic thrombocytopenic purpura (ITP): preliminary data from the EXTEND study. Blood. 2007; 110 (11). Published online, Nov 2007.
(2) McMillan, R., Bussel, JB., et al. Self-reported health-related quality of life in adults with chronic immune thrombocytopenic purpura. Am Hematol. Published online, 23 Aug 2007.
(3) Cines, DB., McMillan, R. Management of adult idiopathic thrombocytopenic purpura. Annu Rev Med. 2005;56: 425-442.
(4) Idiopathic Thrombocytopenic Purpura (ITP) factsheet. Great Ormond Street Hospital for Children NHS Trust. August 2004.
(5) About ITP. Platelet Disorder Support Association (PDSA). Available at http://www.pdsa.org/itp-information/index.html . Accessed 23 November 2007.
(6) Jenkins J, Williams D, Deng Y, et al. Phase I clinical study of eltrombopag, an oral, nonpeptide thrombopoietin receptor agonist. Blood. 2007: 109:4739-4741.
(7) Erickson-Miller, C., Delorme, E., et al Biological Activity and Selectivity for TPO Receptor of the Orally Bioavailable, Small Molecule TPO receptor Agonist, SB-497115. Blood. 2004; 104:796a.
(8) Study TRA105325 protocol.
(9) Bussel, J., Cheng, G., et al. Analysis of Bleeding in Patients with Immune Thrombocytopenic Purpura (ITP): A Randomized, Double-Blind, Placebo-Controlled Trial of Eltrombopag, an Oral Platelet Growth Factor. Blood. 2006; 108: 475.
| SOURCE GlaxoSmithKline Copyright©2007 PR Newswire. All rights reserved |